Glucose Health, Inc. Reports
Fiscal
2021 YTD
Revenue Up
123%
and New Amazon
Sales Record
BENTONVILLE,
AR -- August
9, 2021
-- InvestorsHub NewsWire -- Glucose Health, Inc. (OTC:
"GLUC")
("Company") is pleased to highlight key
financial
information
detailed
in its June
30, 2021
Quarterly
Report,
posted
this
morning at OTCMarkets.com.
- YTD
Fiscal
2021 Revenue
of $524,568
vs.
$234,752 for
YTD
Fiscal 2020 – an
increase of 123%
- Q2
Fiscal 2021 Revenue of $287,103
vs.
$151,139
for
Q2
Fiscal
2020
–
an
increase
of 89%
- YTD
Fiscal
2021
Gross
Profit of $217,794
vs.
$96,886
for
YTD
Fiscal 2020
–
an
increase of 125%
- Q2
Fiscal 2021 Gross Profit of
$102,923
vs.
$69,906
for
YTD
Fiscal 2020
–
an
increase of 47%
GLUCODOWN®
sales at Amazon for
April 2021, the first month of Q2, reached
a
new monthly
record
of $74,944,
beating
the previous
monthly
sales
record of
$38,595 announced by the Company for
June
2020,
by
94%.
Important:
Additional GLUC news updates
to be released in the next two
weeks.
GLUC
will update
shareholders
regarding
the
reduction
of its
fully-diluted
share count by
one-third.
GLUC
will update shareholders regarding the
reduction
of its
outstanding
debt
and liabilities to zero.
About Glucose
Health, Inc. (OTC:
GLUC)
With
a
focus
on creating delicious beverages
nutritionally appropriate1 for
the nation's 100+ million2 pre
and Type-2 diabetics, Glucose
Health, Inc., the manufacturer of GLUCODOWN®, is
uniquely
positioned
among all
emerging beverage
companies in America. Introduced in the third quarter of
2018,
the
GLUCODOWN®
brand
has
established itself
as the market leader for an
entirely new category
– functional,
diabetic
friendly, beverages. Glucose
Health, Inc. is a publicly traded company with the ticker symbol
OTC: GLUC.
To buy
GLUCODOWN® visit our Amazon Store at www.amazon.com/glucodown
Like us on
Facebook at www.facebook.com/glucodown
For more
GLUC information visit
www.glucosehealthinc.com
1
For
citations visit www.glucodown.com/clinical-data
2
National Diabetes Statistics Review, 2020;
Centers for Disease Control and Prevention, Department of Health
and Human Services
This news release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and
while
Glucose
Health, Inc. is not subject to the 1934 Securities and Exchange
Act, contains forward-looking statements within the meaning Section
21E of the Securities and Exchange Act of 1934, as amended.
Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects,"
"anticipates," "intends," "estimates," "plans," "potential,
"possible," "probable, "believes," "seeks," "may, "will, "should,"
"could" or the negative of such terms or other similar expressions.
Actual results may differ materially from those set forth in this
release due to the risks and uncertainties inherent in the
Company's business. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and the Company
undertakes no obligation to revise or update this release to
reflect events or circumstances after the date hereof.
Contact:
Murray
Fleming
Glucose Health,
Inc.
info@glucosehealthinc.com
(479)
802-3827
